AR065582A1 - Mejoras en composiciones medicinales o relativas a las mismas - Google Patents

Mejoras en composiciones medicinales o relativas a las mismas

Info

Publication number
AR065582A1
AR065582A1 ARP080100883A ARP080100883A AR065582A1 AR 065582 A1 AR065582 A1 AR 065582A1 AR P080100883 A ARP080100883 A AR P080100883A AR P080100883 A ARP080100883 A AR P080100883A AR 065582 A1 AR065582 A1 AR 065582A1
Authority
AR
Argentina
Prior art keywords
buprenorphine
nalmefene
same
dosage form
medicinal compositions
Prior art date
Application number
ARP080100883A
Other languages
English (en)
Inventor
Neil Hyde
Christopher Bourne Chapleo
Original Assignee
Reckitt Benckiser Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Reckitt Benckiser Uk Ltd filed Critical Reckitt Benckiser Uk Ltd
Publication of AR065582A1 publication Critical patent/AR065582A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Una composicion analgésica, en una forma de dosificacion parenteral unitaria o en una forma de dosificacion unitaria adecuada para una administracion por la dermis o mucosa, donde dicha composicion comprende buprenorfina y una cantidad de nalmefenotal que la relacion en peso de buprenorfina a nalmefeno administrada o que alcanzo el plasma de un paciente se encuentra en el rango entre 22,6:1 y 40:1. La accion analgésica de buprenorfina es potenciada por la baja dosis de nalmefeno. También seprovee un método de tratamiento del dolor y el uso de nalmefeno y buprenorfina para la elaboracion de un medicamento.
ARP080100883A 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas AR065582A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB0703933A GB2447013A (en) 2007-03-01 2007-03-01 Analgesic composition containing buprenorphone and nalmefene

Publications (1)

Publication Number Publication Date
AR065582A1 true AR065582A1 (es) 2009-06-17

Family

ID=37965707

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100883A AR065582A1 (es) 2007-03-01 2008-02-29 Mejoras en composiciones medicinales o relativas a las mismas

Country Status (22)

Country Link
US (1) US8497280B2 (es)
EP (1) EP2114452B1 (es)
JP (1) JP5577102B2 (es)
KR (1) KR101437461B1 (es)
CN (1) CN101622012B (es)
AR (1) AR065582A1 (es)
AU (1) AU2008220572B2 (es)
BR (1) BRPI0807903A2 (es)
CA (1) CA2678568C (es)
CL (1) CL2008000607A1 (es)
DK (1) DK2114452T3 (es)
ES (1) ES2476865T3 (es)
GB (1) GB2447013A (es)
HK (1) HK1139868A1 (es)
HR (1) HRP20140591T1 (es)
MX (1) MX2009009134A (es)
PE (2) PE20120956A1 (es)
PL (1) PL2114452T3 (es)
PT (1) PT2114452E (es)
TW (1) TWI468163B (es)
WO (1) WO2008104736A1 (es)
ZA (1) ZA200905692B (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102128C2 (en) 2008-12-05 2013-06-10 Х. Луннбек А/С Nalmefene hydrochloride dihydrate
PL2435439T3 (pl) * 2009-05-25 2016-05-31 H Lundbeck As Wytwarzanie chlorowodorku nalmefenu z naltreksonu
CA3120681A1 (en) 2012-04-17 2013-10-24 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN103637983B (zh) * 2013-12-16 2017-08-04 科贝源(北京)生物医药科技有限公司 一种含有盐酸纳美芬的药物组合物及其制备方法
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
CN104922061B (zh) * 2015-05-26 2017-09-22 成都天台山制药有限公司 盐酸纳美芬注射液药物组合物和制法
MX2020008694A (es) * 2018-02-22 2021-01-29 Avior Inc Composicion de pelicula transmucosal y metodos para elaboracion y uso de la misma.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8728294D0 (en) * 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5272149A (en) * 1992-05-05 1993-12-21 Stalling Reginald W Symptom controlled receptor substitution for addiction withdrawl
US6096756A (en) * 1992-09-21 2000-08-01 Albert Einstein College Of Medicine Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
HUP0100310A3 (en) * 1997-12-22 2002-11-28 Euro Celtique Sa A method of preventing abuse of opioid dosage forms
AR031682A1 (es) * 1999-11-19 2003-10-01 Reckitt Benckiser Helthcare Uk Composiciones farmaceuticas
US20050191340A1 (en) * 2002-08-09 2005-09-01 Gruenenthal Gmbh Opioid-receptor antagonists in transdermal systems having buprenorphine
US20100137239A1 (en) * 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) * 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
US20110015168A1 (en) * 2007-01-19 2011-01-20 Mitchell Keegan Methods for increasing levels of human fetal hemoglobin

Also Published As

Publication number Publication date
CN101622012A (zh) 2010-01-06
US20100152222A1 (en) 2010-06-17
JP5577102B2 (ja) 2014-08-20
AU2008220572A1 (en) 2008-09-04
KR20090115862A (ko) 2009-11-09
PL2114452T3 (pl) 2014-09-30
HRP20140591T1 (hr) 2014-09-12
EP2114452A1 (en) 2009-11-11
TWI468163B (zh) 2015-01-11
GB0703933D0 (en) 2007-04-11
CA2678568A1 (en) 2008-09-04
ZA200905692B (en) 2010-10-27
EP2114452B1 (en) 2014-04-09
CA2678568C (en) 2015-06-16
TW200900067A (en) 2009-01-01
MX2009009134A (es) 2009-09-03
HK1139868A1 (en) 2010-09-30
PE20090625A1 (es) 2009-06-04
JP2010520184A (ja) 2010-06-10
CL2008000607A1 (es) 2008-10-03
KR101437461B1 (ko) 2014-09-05
WO2008104736A1 (en) 2008-09-04
PT2114452E (pt) 2014-07-15
AU2008220572B2 (en) 2014-03-27
GB2447013A (en) 2008-09-03
BRPI0807903A2 (pt) 2014-06-17
US8497280B2 (en) 2013-07-30
PE20120956A1 (es) 2012-08-01
ES2476865T3 (es) 2014-07-15
CN101622012B (zh) 2012-05-30
DK2114452T3 (da) 2014-06-30

Similar Documents

Publication Publication Date Title
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR031682A1 (es) Composiciones farmaceuticas
AR075735A1 (es) Composiciones farmaceuticas de liberacion inmediata que comprenden oxicodona y naloxona. uso
AR065582A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
NZ605887A (en) Pharmaceutical dosage form comprising 6’-fluoro-(n-methyl- or n,n-dimethyl-)-4-phenyl-4’,9’-dihydro-3’h-spiro[cyclohexane-1,1’-pyrano[3,4,b]indol]-4-amine for the treatment of neuropathic pain
PE20170302A1 (es) Uso de pridopidina en dosis altas para el tratamiento de enfermedad de huntington
AR065581A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR070047A1 (es) Tratamientos terapeuticos contra el cancer. composicion que comprende un inhibidor de hedgehog.
ES2916649T1 (es) Composiciones y usos para el tratamiento de la esclerosis múltiple
NZ587202A (en) Methods for measuring a patient response upon administration of a drug and compositions thereof
PE20142319A1 (es) Tratamiento de esclerosis multiple con combinacion de laquinimod y acetato de glatiramero
AR065731A1 (es) Composiciones farmaceuticas que contienen 2-[6-(3-amino-pipenidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-primidin-1-il metil]-4-fluoro-benzonitrilo. uso. metodo de tratamiento, administracion semanal de inhibidores de la dipeptidilpeptidasa.
HRP20192189T1 (hr) Doziranja i terapijske primjene l-4-klorokinurenina
AR084093A1 (es) Metodo para tratar los atracones o la ingesta compulsiva de alimentos; uso de buproprion y naltrexona para preparar un medicamento para dichos metodos, y composicion farmaceutica
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR045783A1 (es) Composición farmacéutica que comprende un antagonista del receptor p2x7 y una droga anti-inflamatoria no esteroide
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
BRPI0409380A (pt) composições farmacêuticas
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
AR066666A1 (es) Composicion farmaceutica que comprende la combinacion de un agente antiinflamatorio no esteroideo y un agente anticonvulsivante
AR075866A1 (es) Una dosis de ave5026 para el tratamiento de tromboembolismo venoso en pacientes con deterioro renal severo. uso. composicion farmaceutica.
RU2013105513A (ru) Производные 1-аминоалкилциклогексана для лечения воспалительных заболеваний кожи
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
AR074246A1 (es) Derivados de 1-amino-alquilciclohexano para el tratamiento de trastornos del sueno

Legal Events

Date Code Title Description
FB Suspension of granting procedure